Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Patterson C, Lynch C, Bliss A, et al. World Alzheimer Report 2018. Alzheimer Disease International (ADI). London, UK. Available at: https://www.alz.co.uk/research/world-report-2018.
- NIA-AA research framework: toward a biological definition of Alzheimer's disease.Alzheimers Dement. 2018; 14: 535-562
- Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease.Alzheimers Dement. 2016; 12: 164-169
- Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria.Alzheimers Dement. 2016; 12: 292-323
- Biomarkers for Alzheimer's disease.Curr Alzheimer Res. 2019; 16: 518-528
- Molecular biomarkers of Alzheimer's disease: progress and prospects.Dis Model Mech. 2018; 11 ([pii:dmm031781])
- Drug development in Alzheimer's disease: the path to 2025.Alzheimers Res Ther. 2016; 8: 39
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the World Federation of Societies of biological Psychiatry.World J Biol Psychiatry. 2018; 19: 244-328
- Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.Nat Rev Neurol. 2018; 14: 639-652
- Plasma concentrations of free amyloid beta cannot predict the development of Alzheimer's disease.Alzheimers Dement. 2017; 13: 778-782
- Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.JAMA Neurol. 2017; 74: 557-566
- Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.Alzheimers Dement. 2017; 13: 45-58
- Multiplex immunoassay measurement of amyloid-beta42 to amyloid-beta40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease.Exp Brain Res. 2018; 236: 1241-1250
- Blood-based molecular biomarkers for Alzheimer's disease.Mol Brain. 2019; 12: 26
- Genetics of Alzheimer's disease.Adv Genet. 2014; 87: 245-294
- Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know.Arch Neurol. 1995; 52: 1074-1079
- Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards Subcommittee of the American Academy of Neurology.Neurology. 2001; 56: 1143-1153
- Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease.Neurobiol Aging. 2017; 49: 214.e7-11
- Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.Brain. 2019; 142: 460-470
- Person-specific contribution of neuropathologies to cognitive loss in old age.Ann Neurol. 2018; 83: 74-83
- Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application.Int J Mol Sci. 2019; 20 ([pii:E2812])
- TAR DNA-binding protein 43 in neurodegenerative disease.Nat Rev Neurol. 2010; 6: 211-220
- Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.Brain. 2019; 142: 1503-1527
- Hippocampal sclerosis, argyrophilic grain disease, and primary age-related tauopathy.Continuum (Minneap Minn). 2019; 25: 208-233
- Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 2016; 266: 587-597
- Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric abeta and tau species.Front Neurosci. 2019; 13: 659
- Molecular pathogenesis of the tauopathies.Annu Rev Pathol. 2019; 14: 239-261
- Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.Mol Neurodegener. 2017; 12: 63
- Extracellular vesicles--Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases.Semin Cell Dev Biol. 2015; 40: 89-96
- High complement levels in astrocyte-derived exosomes of Alzheimer disease.Ann Neurol. 2018; 83: 544-552
- Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study.Alzheimer Dis Assoc Disord. 2008; 22: 94-97
- Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: findings from the REVEAL Study.Patient Educ Couns. 2017; 100: 927-935
- Vitamin E and donepezil for the treatment of mild cognitive impairment.N Engl J Med. 2005; 352: 2379-2388
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.Alzheimers Dement. 2011; 7: 367-385
- Elevation of the plasma Abeta40/Abeta42 ratio as a diagnostic marker of sporadic early-onset Alzheimer's disease.J Alzheimers Dis. 2015; 48: 1043-1050
- A two-step immunoassay for the simultaneous assessment of Abeta38, Abeta40 and Abeta42 in human blood plasma supports the Abeta42/Abeta40 ratio as a promising biomarker candidate of Alzheimer's disease.Alzheimers Res Ther. 2018; 10: 121
- Plasma Amyloid as prescreener for the earliest Alzheimer pathological changes.Ann Neurol. 2018; 84: 648-658
- Mechanisms underlying inflammation in neurodegeneration.Cell. 2010; 140: 918-934
- Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.Alzheimers Res Ther. 2015; 7: 59
- YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer's disease.Curr Neuropharmacol. 2017; 15: 906-917
- TREM2 variants in Alzheimer's disease.N Engl J Med. 2013; 368: 117-127
- Soluble TREM2 changes during the clinical course of Alzheimer's disease: a meta-analysis.Neurosci Lett. 2018; 686: 10-16
- sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.EMBO Mol Med. 2016; 8: 466-476
- Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies.J Neurol Neurosurg Psychiatry. 2017; 88: 876-882
- Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease.FASEB J. 2018; 32: 888-893
- Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.Alzheimers Res Ther. 2018; 10: 71
- Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease.Alzheimers Res Ther. 2018; 10: 113
- Plasma neurofilament light chain levels in Alzheimer's disease.Neurosci Lett. 2017; 650: 60-64
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.Nat Med. 2019; 25: 277-283
Article info
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
